Federal law doesn’t clearly preempt Hawaii’s Act 143, which prohibits drugmakers from imposing delivery restrictions on discounted drugs covered by the federal government’s 340B pricing program, the US District Court for the District of Hawaii said Monday. AstraZeneca didn’t show it was likely to win on its argument that the state law conflicts with the federal drug-pricing program because Act 143 deals only with shipping and delivery—a matter not covered by the federal law, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.